Intelligent Bio Solutions (NASDAQ:INBS) versus Co-Diagnostics (NASDAQ:CODX) Head to Head Review

Intelligent Bio Solutions (NASDAQ:INBS) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Profitability

This table compares Intelligent Bio Solutions and Co-Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-323.79%	-146.03%	-83.62%
Co-Diagnostics	-563.93%	-54.94%	-49.28%

Volatility and Risk

Intelligent Bio Solutions has a beta of 4.72, suggesting that its stock price is 372% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500.

Valuation & Earnings

This table compares Intelligent Bio Solutions and Co-Diagnostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$3.03 million	4.76	-$10.16 million	N/A	N/A
Co-Diagnostics	$7.32 million	2.22	-$35.33 million	($1.38)	-0.37

Intelligent Bio Solutions has higher earnings, but lower revenue than Co-Diagnostics.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Intelligent Bio Solutions and Co-Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	0	0	0	0	0.00
Co-Diagnostics	0	1	0	0	2.00

Co-Diagnostics has a consensus target price of $1.50, suggesting a potential upside of 194.70%. Given Co-Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Intelligent Bio Solutions.

Institutional & Insider Ownership

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 0.3% of Intelligent Bio Solutions shares are held by company insiders. Comparatively, 6.1% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Co-Diagnostics beats Intelligent Bio Solutions on 6 of the 11 factors compared between the two stocks.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.